A1 adenosinergic modulation alters the duration of maximal dentate activation.
The role of adenosine systems in the initiation and termination of seizures was examined using a unique marker for limbic seizures--maximal dentate activation (MDA). At 10 mg/kg 2-chloroadenosine shortened the duration of MDA, a measure of seizure terminating processes. The selective A1 agonist, cyclopentyladenosine, at 3 mg/kg, blocked the increase in duration of MDA, while the A1 antagonist, 1,3-dipropyl-8-cyclopentylxanthine (0.05 mg/kg) had the opposite effect. None of the compounds tested altered the time to onset of MDA, a measure of processes that initiate seizures. Therefore, modulation of A1 adenosine systems appears to alter seizure termination much more than seizure initiation.
Stringer
J L
JL
Department of Neurology, University of Virginia Medical Center Charlottesville 22908.
Lothman
E W
EW
D015762:2-Chloroadenosine / Q000494:pharmacology; D000241:Adenosine / Q000031:analogs & derivatives / Q000494:pharmacology; D000818:Animals; D004558:Electric Stimulation; D006624:Hippocampus / Q000187:drug effects*; D008032:Limbic System / Q000187:drug effects*; D008297:Male; D051381:Rats; D011919:Rats, Inbred Strains; D011983:Receptors, Purinergic / Q000187:drug effects / Q000502:physiology*; D012640:Seizures / Q000139:chemically induced / Q000503:physiopathology*; D013997:Time Factors; D014970:Xanthines / Q000494:pharmacology
D011983:Receptors, Purinergic; D014970:Xanthines; D015762:2-Chloroadenosine; C048599:N(6)-cyclopentyladenosine; C053896:1,3-dipropyl-8-(4-sulfophenyl)xanthine; C051360:1,3-dipropyl-8-cyclopentylxanthine; D000241:Adenosine